We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
Read MoreHide Full Article
For Immediate Release
Chicago, IL –October 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Masimo Corporation (MASI - Free Report) , Medtronic PLC (MDT - Free Report) , Garmin Ltd. (GRMN - Free Report) and DexCom, Inc (DXCM - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Wearable Medical Devices Boom Puts These 3 Stocks in Focus
More than half of the American populace uses wearable devices to track calories, measure oxygen saturation (SpO2), monitor sleep, fetal monitoring, pulse rate analysis, maintain blood pressure and self-glucose monitoring.
Per a recent research report by the BrandEssence, the wearable medical devices market was valued at $6.58 billion in 2017 and is expected to reach a worth of $25.46 Billion before 2024, at a CAGR of about 21.32%.
Considering the trends, analysts and tech enthusiasts are expecting significant growth in the wearable medical devices market. Thus, companies involved in the development of wearable medical devices are likely to draw investors’ attention.
Tech Behemoths Reigning the Space
Since the advent of the smartphone, tech companies have been working to apply medical uses to phone-connected, body-mounted sensors.
After the release of Apple’s FDA-approved Watch Series 4 that captures an electrocardiogram seamlessly, Fitbitrecently announced that its latest wearable, Charge 3, is available globally. The product, priced at $149.95, features 24/7 PurePulse heart rate technology that is more advanced, with more than nine trillion minutes of heart rate data. Further, it includes SpO2 sensor that tracks oxygen level in blood, sleeping disorders, allergies and asthma.
Let us take a quick look at three companies from the MedTech space that are gaining momentum in the wearable devices space.
3 MedTech Companies Gaining Momentum
We have zeroed in on three MedTech stocks that have significant exposure towearable technology and are raking in billions.
Masimo Corporation: Masimo is a strong player in the U.S. MedTech space. The company’s wide exposure to wireless technology is supported by its SET Pulse Oximetry platform.
The company’s flagship Radius 7 platform is small, lightweight and wearable for untethered monitoring as well as ambulation. It is used for measuring SpO2 and monitoring pulse rate. The platform leverages on Masimo’s SET Measure-through Motion and Low Perfusion pulse oximetry platform.
Medtronic PLC: Medtronic announced integration with a popular fitness wearable company, Garmin International Inc., a unit of Garmin Ltd.. The company will leverage on Garmin’s wearable device data for remote patient monitoring. Medtronic integrated Garmin data directly into Medtronic Care Management Services' (MCMS) platform.
The collaboration is revolutionary as it synced Garmin vívofit series activity tracker data into the MCMS NetResponse mobile application. This enabled patients and physicians to better manage health conditions from home. Also, it gave healthcare providers to check on patients’ activities at home post discharge from hospital.
In 2016, Medtronic partnered with Fitbit to integrate health and activity tracking for patients suffering from diabetes as well as their physicians and care teams.
The stock has a Zacks Rank #3 (Hold). Medtronic’s shares have returned 26.3% in a year’s time compared with the industry’s return of 20.5%.
DexCom, Inc: The company’s FDA-cleared CGM system — the Dexcom G5 mobile app — for Android devices is a compact CGM System that works seamlessly to display real-time glucose activity on smart phones or watches, tablets and other compatible devices. This makes DexCom’s solutions easy, user friendly and propels its demand.
Apart from this, the company has a very unique application — DexCom Follow App — which enables 5 people to remotely monitor the patient’s glucose data and trends.
DexCom’s shares have outperformed the industry in a year’s time. Notably, the company’s shares have surged 167.4% compared with the industry’s rise of 22.8%. The stock has a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
For Immediate Release
Chicago, IL –October 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Masimo Corporation (MASI - Free Report) , Medtronic PLC (MDT - Free Report) , Garmin Ltd. (GRMN - Free Report) and DexCom, Inc (DXCM - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Wearable Medical Devices Boom Puts These 3 Stocks in Focus
More than half of the American populace uses wearable devices to track calories, measure oxygen saturation (SpO2), monitor sleep, fetal monitoring, pulse rate analysis, maintain blood pressure and self-glucose monitoring.
Per a recent research report by the BrandEssence, the wearable medical devices market was valued at $6.58 billion in 2017 and is expected to reach a worth of $25.46 Billion before 2024, at a CAGR of about 21.32%.
Considering the trends, analysts and tech enthusiasts are expecting significant growth in the wearable medical devices market. Thus, companies involved in the development of wearable medical devices are likely to draw investors’ attention.
Tech Behemoths Reigning the Space
Since the advent of the smartphone, tech companies have been working to apply medical uses to phone-connected, body-mounted sensors.
After the release of Apple’s FDA-approved Watch Series 4 that captures an electrocardiogram seamlessly, Fitbitrecently announced that its latest wearable, Charge 3, is available globally. The product, priced at $149.95, features 24/7 PurePulse heart rate technology that is more advanced, with more than nine trillion minutes of heart rate data. Further, it includes SpO2 sensor that tracks oxygen level in blood, sleeping disorders, allergies and asthma.
Let us take a quick look at three companies from the MedTech space that are gaining momentum in the wearable devices space.
3 MedTech Companies Gaining Momentum
We have zeroed in on three MedTech stocks that have significant exposure towearable technology and are raking in billions.
Masimo Corporation: Masimo is a strong player in the U.S. MedTech space. The company’s wide exposure to wireless technology is supported by its SET Pulse Oximetry platform.
The company’s flagship Radius 7 platform is small, lightweight and wearable for untethered monitoring as well as ambulation. It is used for measuring SpO2 and monitoring pulse rate. The platform leverages on Masimo’s SET Measure-through Motion and Low Perfusion pulse oximetry platform.
Masimo's shares have outperformed the industry in the past year. The stock has rallied 40.4% compared with the industry's increase of 22.9%. The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic PLC: Medtronic announced integration with a popular fitness wearable company, Garmin International Inc., a unit of Garmin Ltd.. The company will leverage on Garmin’s wearable device data for remote patient monitoring. Medtronic integrated Garmin data directly into Medtronic Care Management Services' (MCMS) platform.
The collaboration is revolutionary as it synced Garmin vívofit series activity tracker data into the MCMS NetResponse mobile application. This enabled patients and physicians to better manage health conditions from home. Also, it gave healthcare providers to check on patients’ activities at home post discharge from hospital.
In 2016, Medtronic partnered with Fitbit to integrate health and activity tracking for patients suffering from diabetes as well as their physicians and care teams.
The stock has a Zacks Rank #3 (Hold). Medtronic’s shares have returned 26.3% in a year’s time compared with the industry’s return of 20.5%.
DexCom, Inc: The company’s FDA-cleared CGM system — the Dexcom G5 mobile app — for Android devices is a compact CGM System that works seamlessly to display real-time glucose activity on smart phones or watches, tablets and other compatible devices. This makes DexCom’s solutions easy, user friendly and propels its demand.
Apart from this, the company has a very unique application — DexCom Follow App — which enables 5 people to remotely monitor the patient’s glucose data and trends.
DexCom’s shares have outperformed the industry in a year’s time. Notably, the company’s shares have surged 167.4% compared with the industry’s rise of 22.8%. The stock has a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.